Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
119 hedge funds and large institutions have $424M invested in Keryx Biopharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 18 closing their positions.
68% more call options, than puts
Call options by funds: $6.38M | Put options by funds: $3.8M
24% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 29
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
6% more capital invested
Capital invested by funds: $399M → $424M (+$25.1M)
3% less funds holding
Funds holding: 123 → 119 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$29.6M |
| 2 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$7.14M |
| 3 |
OWIM
Old West Investment Management
Los Angeles,
California
|
+$3.39M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.19M |
| 5 |
Millennium Management
New York
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.57M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.57M |
| 3 |
Bank of New York Mellon
New York
|
-$2.49M |
| 4 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$1.17M |
| 5 |
JP Morgan Chase
New York
|
-$1.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
126
Virtu KCG Holdings
New York
| – | -$140K | -23,870 | Closed |
|
|
ST
127
Spot Trading
Chicago,
Illinois
| – | -$115K | -19,646 | Closed |
|
128
HSBC Holdings
London,
United Kingdom
| – | -$80K | -13,600 | Closed |
|
129
ProShare Advisors
Bethesda,
Maryland
| – | -$74K | -12,682 | Closed |
|
|
FRM
130
Fox Run Management
Greenwich,
Connecticut
| – | -$62K | -10,600 | Closed |
|
131
Simplex Trading
Chicago,
Illinois
| – | -$38.7K | -7,057 | Closed |
|
|
TRCT
132
Tower Research Capital (TRC)
New York
| – | -$35K | -5,911 | Closed |
|
|
MFW
133
Mosaic Family Wealth
St. Louis,
Missouri
| – | -$9K | -1,500 | Closed |
|
|
CSS
134
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$8K | -1,409 | Closed |
|
|
CG
135
Cutler Group
San Francisco,
California
| – | -$6.6K | -1,205 | Closed |
|
|
HI
136
Hudock Inc
Williamsport,
Pennsylvania
| – | -$1.92K | -350 | Closed |
|
|
PHK
137
Point72 Hong Kong
Hong Kong
| – | -$1K | -100 | Closed |
|
KERX Hedge Fund Activity: Q1 2017 in Review
119 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2017, worth a combined $424M — up 6.3% from $399M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KERX positions and 18 closed out — a net gain of 2 holders — while 36 added to existing stakes and 29 trimmed.
The largest buyer was BlackRock, adding an estimated $29.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.57M sold.
- 119 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2017, down from 123 in Q4 2016.
- Funds reported $424M of Keryx Biopharmaceuticals Inc stock for Q1 2017, up 6.3% quarter-over-quarter.
- 20 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2017 and 18 closed out, a net change of +2 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $29.6M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q1 2017 was Deerfield Management, an estimated $7.57M sold.
Based on aggregated 13F filings for Q1 2017.